Astria Therapeutics, Inc. (ATXS)
$12.58+0.00%Close
SELLBEAR · day 8
Key stats
- Market cap
- $718M
- Beta
- 0.02
- P/E (TTM)
- -11.23
- 1W
- -1.80%
- 1M
- -2.63%
- vs SPY 1W
- -2.96%
- vs SPY 1M
- -5.62%
Industry peers
FMP comparable companies · ranked by market cap
- IOVABUYIovance Biotherapeutics, Inc.$6.5BRECOVERYQ 9$14.62+9.84%
- ERASSELLErasca, Inc.$5.6BRECOVERYQ 4$16.03+3.69%
- MBXSELLMBX Biosciences, Inc. Common Stock$2.5BCRISISQ 38$53.24-0.02%
- DAWNDay One Biopharmaceuticals, Inc.$2.2B$21.53
- REPLSELLReplimune Group, Inc.$1.1BRECOVERYQ 14$13.42+2.91%
- MGTXSELLMeiraGTx Holdings plc$990MCRISISQ 6$10.69+1.81%
- DNABUYGinkgo Bioworks Holdings, Inc.$849MRECOVERYQ -16$13.00+14.64%
- AVBPSELLArriVent BioPharma, Inc.$779MCRISISQ -5$16.73+0.12%
- VALNSELLValneva SE$548MCRISISQ -0$5.78+1.58%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on ATXS?
- LOPJLB’s latest quantitative signal on Astria Therapeutics, Inc. (ATXS) is SELL in a BEAR regime. Signals are updated daily.
- What market regime is ATXS in?
- Astria Therapeutics, Inc. (ATXS) is currently classified in the BEAR HMM market regime on LOPJLB.
- What does Astria Therapeutics, Inc. (ATXS) do?
- Astria Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, established in 2008. The firm specializes in identifying, advancing, and bringing to market treatments for uncommon and specialized allergic and immunological disorders across the United States. Its leading experimental drug, STAR-0215, is a monoclonal antibody that targets and inhibits plasma kallikrein. T…